Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib with subcutaneous amivantamab versus intravenous amivantamab in EGFR-mutated advanced or metastatic non-small cell lung cancer after osimertinib and chemotherapy
2024-512045-16-00Phase 3Authorised
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of lazertinib and amivantamab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Ctrough of amivantamab and AUCD1-D15 in Cycle 2. Planned start Aug 2022; status: authorised.
02
Drugs
lazertinibamivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-512045-16-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512045-16-00.